SG11201407791VA - Genotype- or phenotype-based drug formulation - Google Patents
Genotype- or phenotype-based drug formulationInfo
- Publication number
- SG11201407791VA SG11201407791VA SG11201407791VA SG11201407791VA SG11201407791VA SG 11201407791V A SG11201407791V A SG 11201407791VA SG 11201407791V A SG11201407791V A SG 11201407791VA SG 11201407791V A SG11201407791V A SG 11201407791VA SG 11201407791V A SG11201407791V A SG 11201407791VA
- Authority
- SG
- Singapore
- Prior art keywords
- internationales
- internationale
- der
- fiir
- dem
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C213/08—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions not involving the formation of amino groups, hydroxy groups or etherified or esterified hydroxy groups
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Computational Biology (AREA)
- Theoretical Computer Science (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Medical Informatics (AREA)
- Evolutionary Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Physiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Pregnancy & Childbirth (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
(12) NACH DEM VERTRAG UBER DIE INTERNATIONALE ZUSAMMENARBEIT AUF DEM GEBIET DES PATENTWESENS (PCT) VEROFFENTLICHTE INTERNATIONALE ANMELDUNG (19) Weltorganisation fiir geistiges Eigentum Internationales Biiro _ (10) Internationale Veroffentlichungsnummer (43) Internationales Veroffentlichungsdatum 5. Dezember 2013 (05.12.2013) WIPOIPCT WO 2013/178565 A1 (51) Internationale Patentklassifikation: A61K31/138 (2006.01) A61P 35/00 (2006.01) (21) Internationales Aktenzeichen: PCT/EP2013/060824 (22) Internationales Anmeldedatum: 27. Mai 2013 (27.05.2013) (25) Einreichungssprache: (26) Veroffentlichungssprache: Deutsch Deutsch (30) Angaben zur Prioritat: 12170401.9 l.Juni 2012 (01.06.2012) EP (71) Anmelder: BAYER TECHNOLOGY SERVICES GMBH [DE/DE]; 51368 Leverkusen (DE). (72) Erflnder: WILLMANN, Stefan; Seidenweg 41, 40593 Diisseldorf (DE). EIBING, Thomas; Kirschbaum 15, 40764 Langenfeld (DE). DICKSCHEN, Kristin; Cheruskerstr. 33, 40545 Diisseldorf (DE). (74) Anwalt: MAUDRIN-LUDEWIG, Jeanne; BIP Patents, c/o Bayer Intellectual Property GmbH, Creative Campus Monheim, Alfred-Nobel-Str. 10, 40789 Monheim (DE). (81) Bestimmungsstaaten (soweit nicht anders angegeben, fiir jede verfiigbare nationale Schutzrechtsart): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Bestimmungsstaaten (soweit nicht anders angegeben, fiir jede verfiigbare regionale Schutzrechtsart)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), eurasisches (AM, AZ, BY, KG, KZ, RU, TJ, TM), europaisches (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Erklarungen gemaB Regel 4.17: — hinsichtlich der Berechtigung des Anmelders, ein Patent zu beantragen und zu erhalten (Regel 4.17 Ziffer ii) Veroffentlicht: — mit internationalem Recherchenbericht (Artikel 21 Absatz V 00 l> i-H en i-H o CJ o & (54) Title: GENOTYPE- OR PHENOTYPE-BASED DRUG FORMULATION (54) Bezeichnung : GENOTYP- BZW. PHANOTYP-BASIERTE ARZEIMITTELFORMULIERUNGEN (57) Abstract: The invention relates to a combination of two or more pharmaceutically active substances, of which at least one is a metabolic product (\"metabolite\") of the other (\"parent substance\"), in particular wherein the dosages thereof are selected in such a way that a genotypically or phenotypically determined variability of the conversion of the parent substance into the metabolite in certain individuals compensated. is (57) Zusammenfassung: Die Erfindung betrifft eine Kombination aus zweien oder mehreren pharmazeutisch aktiven Substanzen, von denen mindestens eine ein Stoffwechselprodukt („Metabolit\") der anderen („Muttersubstanz\") ist, insbesondere wobei deren Dosierungen derart gewahlt werden, dass eine geno- bzw. phanotypisch bedingte Variability der Umsetzung der Muttersubstanz zu dem Metaboliten in bestimmten Individuen kompensiert wird.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12170401.9A EP2668945A1 (en) | 2012-06-01 | 2012-06-01 | Genotype and phenotype-based medicinal formulations |
| PCT/EP2013/060824 WO2013178565A1 (en) | 2012-06-01 | 2013-05-27 | Genotype- or phenotype-based drug formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201407791VA true SG11201407791VA (en) | 2015-01-29 |
Family
ID=48520964
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201610072UA SG10201610072UA (en) | 2012-06-01 | 2013-05-27 | Genotype- or phenotype-based drug formulation |
| SG11201407791VA SG11201407791VA (en) | 2012-06-01 | 2013-05-27 | Genotype- or phenotype-based drug formulation |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201610072UA SG10201610072UA (en) | 2012-06-01 | 2013-05-27 | Genotype- or phenotype-based drug formulation |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US10285958B2 (en) |
| EP (2) | EP2668945A1 (en) |
| JP (2) | JP6096289B2 (en) |
| KR (1) | KR102129043B1 (en) |
| CN (2) | CN110075097A (en) |
| AR (2) | AR091234A1 (en) |
| AU (1) | AU2013269793B2 (en) |
| BR (1) | BR112014030059B1 (en) |
| CA (1) | CA2875189C (en) |
| DK (1) | DK2854789T3 (en) |
| ES (1) | ES2744306T3 (en) |
| HK (1) | HK1207296A1 (en) |
| HU (1) | HUE045699T2 (en) |
| IL (1) | IL235988B (en) |
| MX (1) | MX370304B (en) |
| NZ (1) | NZ702849A (en) |
| PL (1) | PL2854789T3 (en) |
| PT (1) | PT2854789T (en) |
| RU (1) | RU2683260C2 (en) |
| SA (1) | SA113340607B1 (en) |
| SG (2) | SG10201610072UA (en) |
| TW (1) | TWI644666B (en) |
| WO (1) | WO2013178565A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2668945A1 (en) * | 2012-06-01 | 2013-12-04 | Bayer Technology Services GmbH | Genotype and phenotype-based medicinal formulations |
| US11965206B2 (en) | 2018-12-21 | 2024-04-23 | John Stoddard | Method of dosing a patient with multiple drugs using adjusted phenotypes of CYP450 enzymes |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1317546C (en) * | 1985-07-01 | 1993-05-11 | Werner Meier | Pharmaceutical preparations containing mixtures of hydroxy derivatives of vitamin d |
| US6048857A (en) | 1989-10-17 | 2000-04-11 | Ellinwood, Jr.; Everett H. | Dosing method of administering medicaments via inhalation administration |
| US5580728A (en) | 1994-06-17 | 1996-12-03 | Perlin; Mark W. | Method and system for genotyping |
| US6017963A (en) * | 1995-11-14 | 2000-01-25 | Euro-Celtique, S.A. | Formulation for intranasal administration |
| US6760708B1 (en) | 1999-08-19 | 2004-07-06 | Dell Products L.P. | Method and system for migrating stored data to a build-to-order computing system |
| EP1248832A4 (en) | 2000-01-21 | 2004-07-07 | Variagenics Inc | IDENTIFICATION OF GENETIC COMPONENTS IN DRUG REACTION |
| US7427480B2 (en) | 2002-03-26 | 2008-09-23 | Perlegen Sciences, Inc. | Life sciences business systems and methods |
| JP2007504131A (en) * | 2003-08-29 | 2007-03-01 | エートン ファーマ インコーポレーティッド | Combination treatment of cancer |
| US7504214B2 (en) * | 2003-09-19 | 2009-03-17 | Biotheranostics, Inc. | Predicting outcome with tamoxifen in breast cancer |
| DE10345836A1 (en) | 2003-10-02 | 2005-04-21 | Bayer Technology Services Gmbh | Method for simulating the interaction of chemical substances with living organisms |
| JP4732683B2 (en) | 2003-12-29 | 2011-07-27 | ユニバーサル・バイオ・リサーチ株式会社 | Target substance detection method |
| JP4689660B2 (en) | 2004-03-18 | 2011-05-25 | ファンダツィオーネ ィルックス インスティチュート ナツィオナレ デイ ツモリ | 4-Oxo-fenretinide used alone and in combination with fenretinide as a prophylactic and therapeutic agent for cancer |
| WO2005094363A2 (en) | 2004-03-30 | 2005-10-13 | New York University | System, method and software arrangement for bi-allele haplotype phasing |
| DE102004025534A1 (en) | 2004-05-25 | 2005-12-15 | Bayer Technology Services Gmbh | Method for (two-stage) dose and dosage finding |
| US8024128B2 (en) | 2004-09-07 | 2011-09-20 | Gene Security Network, Inc. | System and method for improving clinical decisions by aggregating, validating and analysing genetic and phenotypic data |
| US8147615B2 (en) | 2004-11-05 | 2012-04-03 | Infineon Technologies Ag | Method of fabricating semiconductor cleaners |
| KR20080013927A (en) * | 2005-06-02 | 2008-02-13 | 바이오베일 라보라토리즈 인터내셔널 에스알엘 | Modified release composition of one or more forms of venlafax |
| US20070122824A1 (en) | 2005-09-09 | 2007-05-31 | Tucker Mark R | Method and Kit for Assessing a Patient's Genetic Information, Lifestyle and Environment Conditions, and Providing a Tailored Therapeutic Regime |
| EP1938231A1 (en) | 2005-09-19 | 2008-07-02 | BG Medicine, Inc. | Correlation analysis of biological systems |
| RU2318508C2 (en) * | 2005-12-28 | 2008-03-10 | Всеволод Иванович Киселев | Pharmaceutical composition for preventing and treating proliferative mammary gland diseases |
| FR2896896B1 (en) | 2006-02-02 | 2009-09-25 | Commissariat Energie Atomique | METHOD FOR CLASSIFYING EVENTS OR STATEMENTS IN TWO STEPS |
| DE102006028232A1 (en) | 2006-06-20 | 2007-12-27 | Bayer Technology Services Gmbh | Apparatus and method for calculating and providing a dose of medicament |
| HUE037109T2 (en) | 2006-11-21 | 2018-08-28 | Jina Pharmaceuticals Inc | Endoxifen for use in the treatment of cancer |
| US20090291134A1 (en) | 2006-11-21 | 2009-11-26 | Jina Pharmaceuticals, Inc. | Endoxifen methods and compositions in the treatment of psychiatric and neurodegenerative diseases |
| US8099298B2 (en) | 2007-02-14 | 2012-01-17 | Genelex, Inc | Genetic data analysis and database tools |
| WO2009108802A2 (en) | 2008-02-26 | 2009-09-03 | Purdue Research Foundation | Method for patient genotyping |
| WO2009120999A2 (en) * | 2008-03-28 | 2009-10-01 | Olema Pharmaceuticals, Inc. | Use of an endoxifen prodrug for treatment of breast cancer |
| US20100029734A1 (en) * | 2008-05-06 | 2010-02-04 | Ore Pharmaceuticals Inc. | Methods for breast cancer screening and treatment |
| AU2009267052B2 (en) | 2008-06-30 | 2013-07-11 | Tocagen Inc. | Formulations of 5-fluorocytosine and uses thereof |
| JP4517312B2 (en) * | 2008-07-08 | 2010-08-04 | ソニー株式会社 | Memory access control device and imaging device |
| US20110136913A1 (en) * | 2008-08-19 | 2011-06-09 | Goetz Matthew P | Assessing and treating breast cancer patients |
| US8275442B2 (en) | 2008-09-25 | 2012-09-25 | Zeltiq Aesthetics, Inc. | Treatment planning systems and methods for body contouring applications |
| US7873482B2 (en) | 2008-12-16 | 2011-01-18 | Bruno Stefanon | Diagnostic system for selecting nutrition and pharmacological products for animals |
| US20120088247A1 (en) | 2009-02-23 | 2012-04-12 | Indian University Research & Technology Corporatio | Materials and methods for treating patients with taxoxifen |
| WO2011072244A1 (en) * | 2009-12-10 | 2011-06-16 | Mount Sinai School Of Medicine Of New York University | Method of treatment of breast cancer with tamoxifen |
| US9372198B2 (en) | 2010-06-17 | 2016-06-21 | Aradigm Corporation | Diagnosis of entry of gastrointestinal contents into respiratory tract of humans and animals |
| MX349974B (en) * | 2010-08-26 | 2017-08-22 | Ipca Laboratories Ltd * | Methods for the treatment or prophylaxis of thrombosis or embolism. |
| CA2839608C (en) * | 2011-06-27 | 2020-07-14 | Ipca Laboratories Limited | (7as,2's)-2-oxoclopidogrel as anti-thrombotic compounds |
| CN108048521B (en) | 2012-04-02 | 2022-05-27 | 博格有限责任公司 | Interrogative cell-based assays and uses thereof |
| EP2668945A1 (en) | 2012-06-01 | 2013-12-04 | Bayer Technology Services GmbH | Genotype and phenotype-based medicinal formulations |
| US9417221B2 (en) | 2013-08-27 | 2016-08-16 | International Business Machines Corporation | Food steganography |
-
2012
- 2012-06-01 EP EP12170401.9A patent/EP2668945A1/en not_active Withdrawn
-
2013
- 2013-05-27 DK DK13725157.5T patent/DK2854789T3/en active
- 2013-05-27 SG SG10201610072UA patent/SG10201610072UA/en unknown
- 2013-05-27 JP JP2015514441A patent/JP6096289B2/en active Active
- 2013-05-27 PL PL13725157T patent/PL2854789T3/en unknown
- 2013-05-27 CN CN201910317702.5A patent/CN110075097A/en active Pending
- 2013-05-27 PT PT13725157T patent/PT2854789T/en unknown
- 2013-05-27 BR BR112014030059-3A patent/BR112014030059B1/en active IP Right Grant
- 2013-05-27 NZ NZ702849A patent/NZ702849A/en unknown
- 2013-05-27 ES ES13725157T patent/ES2744306T3/en active Active
- 2013-05-27 MX MX2014014596A patent/MX370304B/en active IP Right Grant
- 2013-05-27 EP EP13725157.5A patent/EP2854789B1/en active Active
- 2013-05-27 HU HUE13725157A patent/HUE045699T2/en unknown
- 2013-05-27 SG SG11201407791VA patent/SG11201407791VA/en unknown
- 2013-05-27 RU RU2014154140A patent/RU2683260C2/en active
- 2013-05-27 AU AU2013269793A patent/AU2013269793B2/en active Active
- 2013-05-27 CN CN201380040850.8A patent/CN104507464A/en active Pending
- 2013-05-27 WO PCT/EP2013/060824 patent/WO2013178565A1/en active Application Filing
- 2013-05-27 CA CA2875189A patent/CA2875189C/en active Active
- 2013-05-27 KR KR1020147036212A patent/KR102129043B1/en active Active
- 2013-05-27 US US14/403,823 patent/US10285958B2/en active Active
- 2013-05-31 AR ARP130101928 patent/AR091234A1/en unknown
- 2013-05-31 TW TW102119266A patent/TWI644666B/en active
- 2013-06-01 SA SA113340607A patent/SA113340607B1/en unknown
-
2014
- 2014-11-30 IL IL235988A patent/IL235988B/en active IP Right Grant
-
2015
- 2015-08-17 HK HK15107896.3A patent/HK1207296A1/en unknown
-
2016
- 2016-11-09 JP JP2016219156A patent/JP2017048234A/en active Pending
-
2017
- 2017-01-31 US US15/420,733 patent/US20170326080A1/en not_active Abandoned
- 2017-06-16 US US15/625,553 patent/US20170326081A1/en not_active Abandoned
-
2020
- 2020-04-30 AR ARP200101246A patent/AR118842A2/en not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201907804QA (en) | Pharmaceutical composition comprising selexipag | |
| SG11201806745RA (en) | Sulfonylureas and related compounds and use of same | |
| SG11201805940QA (en) | Benzopyrazole compounds and analogues thereof | |
| SG11201811442UA (en) | Formulation of a peptide vaccine | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
| SG11201806583XA (en) | Compositions containing tucaresol or its analogs | |
| SG11201807827VA (en) | Process for the preparation of pegylated drug-linkers and intermediates thereof | |
| SG11201900228YA (en) | Administration and dosage of diaminophenothiazines | |
| SG11201901986SA (en) | Process for the manufacture of a solid pharmaceutical adminstration form | |
| SG11201901558VA (en) | Pth compounds with low peak-to-trough ratios | |
| SG11201803949RA (en) | Novel pharmaceutical composition comprising particles comprising a complex of a double-stranded polyribonucleotide and a polyalkyleneimine | |
| SG11201806424TA (en) | Therapeutic compounds | |
| SG11201900238UA (en) | Compounds and methods for modulation of smn2 | |
| SG11201903076QA (en) | Carbamoyl phenylalaninol compounds and uses therof | |
| SG11201407728RA (en) | Pul-core method with a pmi foam core | |
| SG11201908691PA (en) | Compounds and methods for the treatment of parasitic diseases | |
| SG11201805423TA (en) | Indolinones compounds and their use in the treatment of fibrotic diseases | |
| SG11201804587QA (en) | Isoindole compounds | |
| SG11201803915UA (en) | Echinomycin formulation, method of making and method of use thereof | |
| SG11202000494UA (en) | Drug delivery composition | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201901048VA (en) | Pharmaceutical compositions and uses directed to lysosomal storage disorders | |
| SG11201803702TA (en) | Phantoms having reference members with microchannels and diffusion weighted imaging using same | |
| SG11202000141WA (en) | Powder solid dispersions comprising quercetin, process for their preparation and formulations thereof |